Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics and diagnostics from human biomedical research and developing them to address unmet needs in the veterinary market for companion animals – horses, dogs and cats.
Our mission statement adheres to the “one health” concept, reflective of the inherent synergies between animal and human medicine.
Developing new medicines to address unmet needs in animal health.
Developing new veterinary diagnostics to identify disorders in dogs, cats and horses.
Corporate Social Responsibility
Poïesis contributes a percentage of its profits to chosen charities which are making a difference for humans and animals.
First Phase Goal of $115M Receiving Strong Philanthropic Support By Laura Pizzo, Senior Manager of Communications, UC Davis, October 13, 2017 The University of California, Davis, today announced plans to raise $115 million in philanthropic support to...read more
By Michael Helmstetter, Ph.D., President and CEO, TechAccel, July 27, 2017. Many investors who are interested in the animal health space still feel they don’t know the industry well enough to make smart investments. The feeling is understandable. Animal health is an...read more
By Cathy Yarbrough, Contributing Editor For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership...read more
Anne Weintraub, Contributor, September 14, 2017 At the third International Cancer Immunotherapy Conference in Frankfurt last week, Ellen Puré may have seemed a bit out of place as professor and director at the University of Pennsylvania School of...read more
Rise of pet owners reflects growing incomes in developing world Steve Johnson, August 27, 2017 Pet ownership has risen dramatically in developing countries this millennium, even as it has remained little changed in the developed world. The trend is...read more
Following on its move from London to San Diego, California, Poïesis has opened its Seed Round of financing seeking to raise $5 million to complete in-licensing and initiate clinical development of its therapeutic and diagnostic pipeline in several indications in dogs,...read more
By Mary Guiden, Communications Coordinator, Coleman Cornelius, Director of Communications and Dell Rae Ciaravola, Senior Media and Community Relations Coordinator The backdrop of storm clouds added to the atmosphere of import as Colorado State University leaders and...read more
By Joseph Harvey, 20 April 2017. So far, 2017 has said farewell to Merial and seen the purchase of Nexvet Biopharma – two very different companies in the animal health space. Animal Pharm editor Joseph Harvey takes a closer look at these two transactions and their...read more
Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market. By Jenny Rood | October 1, 2016. Around Christmas 2010, University of Minnesota researcher Mark Suckow received terrible news:...read more
Poïesis Therapeutics Selected as a Finalist for CONNECT’s 30th Annual Most Innovative New Product Awards
Products to treat dry-eye and fungal disease are the first of novel nanoparticle-based medicines being developed in portfolio of pet medications Company is using data from innovative human drugs to efficiently bring better quality healthcare to the veterinary market...read more
Poïesis Therapeutics Successfully Completes CONNECT Internationally Acclaimed Springboard Accelerator Program SAN DIEGO, July 18, 2017 -- Poïesis Therapeutics, a biotechnology start-up in the pet health industry, is pleased to announce that the company has...read more
Company Chosen to Compete at Group's Annual Holiday Dinner Following Lengthy Selection Process From 120 Applicants SAN DIEGO, December 1, 2016 -- Poïesis Therapeutics, a biotechnology start-up in the pet health industry, is pleased to announce that the company...read more